Celyad Oncology (XBRU:CYAD) Institutional Ownership : 0.24% (As of May. 22, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celyad Oncology's institutional ownership is 0.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celyad Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celyad Oncology's Float Percentage Of Total Shares Outstanding is 78.28%.

Celyad Oncology Institutional Ownership Historical Data

The historical data trend for Celyad Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Institutional Ownership Chart

Celyad Oncology Historical Data

The historical data trend for Celyad Oncology can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.32	0.32	0.32	0.38	0.35	0.18	0.18	0.24	0.24	0.24

Celyad Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Celyad Oncology (XBRU:CYAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

1C0:Germany

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines